Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Thienodiazepines are described as extremely addictive with significant abuse potential. Compulsive redosing is a commonly reported effect, and tolerance to sedative-hypnotic effects develops within a couple days of repeated administration.
Physical dependence develops with regular use. Abrupt discontinuation can be potentially dangerous or life-threatening, sometimes resulting in seizures or death. Withdrawal symptoms include rebound anxiety and insomnia. Gradual tapering over weeks is strongly recommended for regular users.
The lethal dosage has not been established. Like many benzodiazepines, metizolam appears to have a large therapeutic index and margin of safety when used alone. However, overdose can lead to coma, permanent brain injury, or death, particularly when combined with other depressants.
Paradoxical reactions including violent behavior, loss of impulse control, and irritability occur rarely, with an incidence rate below 1% in the general population. These occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dose regimes. Delusions may occur during overdose.
Seizure risk is primarily associated with abrupt discontinuation following regular use, which can be life-threatening. Paradoxical seizures during use are rare, occurring with greater frequency in epileptics. Drugs that lower the seizure threshold should be avoided during withdrawal.
Metizolam was first patented in 1995 by a Japanese pharmaceutical company as a potential medication for treating anxiety disorders. Despite this early patent, the compound was never developed for clinical use and has no documented history of medical application.…
Controlled under the Controlled Drugs and Substances Act. All benzodiazepine compounds are classified as Schedule IV controlled substances in Canada, which restricts possession, trafficking, and importation.
Classified as an illegal substance on January 26, 2016, following its emergence on the designer drug market. Possession, sale, and distribution are prohibited.
Classified as a controlled drug under Turkish narcotics legislation. Possession, production, supply, and importation are all prohibited activities.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, importation with intent to distribute, administration to others, and trafficking are criminally punishable offenses. Possession is prohibited but does not carry criminal penalties.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics scheduling. Production, distribution, and possession without authorization are prohibited.
Production, supply, and importation are prohibited under the Psychoactive Substances Act 2016, effective May 26, 2016. This blanket legislation covers psychoactive substances not specifically exempted. Personal possession is not criminalized under this act.
11 sources cited